YFYang Fu

Yang Fu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yang Fu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Haidong Zou

    Department of Ophthalmology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    1 shared publication
  • Min Tang

    Department of Ophthalmology, Shanghai Jiaotong University Affiliated First People's Hospital, Shanghai, China, 200080

    1 shared publication
  • Min Tang

    Department of Ophthalmology, Shanghai General Hospital of Nanjing Medical University, Shanghai, China

    1 shared publication
  • Min Tang

    Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200080, P.R. China

    1 shared publication
  • Xiaodong Sun

    Department of Ophthalmology, Shanghai Jiaotong University Affiliated First People's Hospital, Shanghai, China, 200080

    1 shared publication
  • Xiaodong Sun

    Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    1 shared publication

Latest Publications

  • Open Access

    Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma

    by Min Tang, Yang Fu, Ying Wang, Zhi Zheng, Ying Fan, Xiaodong Sun, Xun Xu

    Neovascular glaucoma is a refractive glaucoma. Recently, anti-VEGF factors have been used alone or in combination for the treatment of neovascular glaucoma. However, the medium- and long-term efficacy of such drugs remains to be evaluated. This study was to determine the efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma. In this prospective non-randomized study, 43 neovascular glaucoma patients (43 eyes) were assigned to receive either 0.5 mg intravitreal ranibizumab for three to 14 days before Ahmed glaucoma valve implantation (injection group, n = 21) or Ahmed glaucoma valve implantation alone (control group, n = 22). The patients were followed up for six to 12 months. Differences in surgical success rate, intraocular pressure, best corrected visual acuity, anti-glaucoma medications and postoperative complications were compared between the two groups. Surgical success was defined as IOP > = 6 mm Hg and < = 21 mm Hg, with or without the use of anti-glaucoma medications, and without severe complications or reoperation. Of the 43 patients, 40 completed the 6-month follow-up and 37 completed the 1-year follow-up. Success rate was 73.7 % vs. 71.4 % at six months and 72.2 % vs. 68.4 % at 12 months in the injection group and the control group respectively. No significant difference was noted between the two groups (six months: P = 0.87, 12 months: P = 1.00). There were no significant differences in the two groups with respect to intraocular pressure, best corrected visual acuity, anti-glaucoma medications or postoperative complications at six months or 12 months. Single intravitreal ranibizumab (0.5 mg) before surgery has no significant effect on the medium- or long-term outcomes of neovascular glaucoma treated with Ahmed glaucoma valve implantation. Chinese Clinical Trial Registry ( ChiCTR-OOC-14005709 , Trial registration date: 2014-12-01)


  • Anti-apoptotic effects of melatonin in retinal pigment epithelial cells

    by Yang Fu, Min Tang, Ying Fan, Haidong Zou, Xiaodong Sun, Xun Xu

    Recent studies have revealed that melatonin exerts strong anti-apoptotic effects. Retina secretes melatonin, and melatonin receptors are distributed in almost all the layers of retina, including the layer of retinal pigment epithelial (RPE) cells. However, it is not known whether melatonin inhibits apoptosis through its anti-oxidant effects and how it works in RPE cells. Here, we show that melatonin decreases H2O2-induced apoptosis in RPE cells partially through protection of mitochondria. Melatonin decreased reactive oxygen species in mitochondria and mitochondrial DNA damage, alleviated structural damage and inhibited cytochrome C release.